Australia, June 30 -- Larimar Therapeutics Inc., owns the trademark (2613289) for 'FRAXLANZA' till Nov. 21, 2035.
Status: protected:
Registered/protected
Class: 5 [Pharmaceutical preparations for the treatment of mitochondrial disorders; pharmaceutical preparations and substances for treatment of genetic diseases; pharmaceutical preparations for the treatment of diseases or dysfunction of the mitochondria; pharmaceutical preparations featuring cell penetrating peptides for use in the treatment of genetic disorders; pharmaceuticals that treat genetic diseases by use of carrier proteins; pharmaceutical preparations for the treatment of ataxia; pharmaceutical preparations for the treatment of Friedreich's Ataxia; pharmaceutical preparations for protein replacement therapy; pharmaceutical preparations for frataxin replacement therapy.]
Type of Mark: Word
Date of Acceptance: Feb. 20
Registration Advertised: June 29
For further details contact Keith Toms, Esq. McCarter & English LLP .
The original document can be viewed at: https://search.ipaustralia.gov.au/trademarks/search/view/2613289.
Disclaimer: Curated by HT Syndication.
